Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD
מצבים רפואיים
Group 3 Pulmonary Hypertension
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Hualien Tzu Chi Hospital, Hualien City, Taiwan
Contact: Principal Investigator (Wei-Hsin Liu, M.D.)Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan
Contact: Principal Investigator (Kun-Chang Lin, MD)Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
Contact: Principal Investigator (Chun-Yuan Chu, M.D.)Taichung Veterans General Hospital, Taichung, Taiwan
Contact: Principal Investigator (Pin-Kuei Fu, M.D.)National Cheng Kung University Hospital, Tainan, Taiwan
Contact: Principal Investigator (Chih-Hsin Hsu, MD)National Taiwan University Hospital, Taipei, Taiwan
Contact: Principal Investigator (Ping-Hung Kuo, M.D.)MacKay Memorial Hospital, Taipei, Taiwan
Contact: Principal Investigator (Yih-Jer Wu, MD)Taipei Veterans General Hospital, Taipei, Taiwan
Contact: Principal Investigator (Shih-Hsien Sung, M.D.)Chang Gung Memorial Hospital - Linkou Branch, Taoyuan City, Taiwan
Contact: Principal Investigator (Wan-Jing Ho, M.D.)
מובילי המחקר
Bassem Elmankabadi, MD
Study Director
Foresee Pharmaceuticals